Robert Mitchell, MD
Cardiovascular Disease · Kalispell, MTNPI 1750399564
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,250 of the $22,762 with a category attached, or 89.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 89.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $12,353 and has fallen 97.6% since, to $292 in 2025. Among cardiovascular disease clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $172.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
- Biotronik Inc.$2K
- Johnson & Johnson$129
- E.r. Squibb & Sons, L.L.C.$116
- AstraZeneca$59
- Sanofi-aventis U.S. LLC$49
- plus $286 from 12 others
What the payments were for
- Speaking & faculty fees$20,25089%
- Food & beverage$2,51211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $20,442 |
| Biotronik Inc. | 70 | $1,682 |
| Johnson & Johnson | 8 | $129 |
| E.r. Squibb & Sons, L.L.C. | 7 | $116 |
| AstraZeneca | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Mylan Specialty L.p. | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Amgen | 3 | $36 |
| La Jolla Pharmaceutical Company | 2 | $34 |
| Boston Scientific | 1 | $28 |
| Chiesi USA, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$20,250
How this compares
$22,762 in reported general payments places this provider in the 95th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $284,728 |
| XareltoRivaroxaban | 129 | $135,566 |
| Repatha SureclickEvolocumab | 130 | $89,220 |
| MultaqDronedarone Hcl | 13 | $17,949 |
| Dofetilide | 25 | $15,437 |
| EntrestoSacubitril/Valsartan | 16 | $13,397 |
| Praluent PenAlirocumab | 22 | $10,770 |
| Repatha SyringeEvolocumab | 11 | $9,079 |
| Flecainide Acetate | 166 | $5,135 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $3,740 |
| Metoprolol Succinate | 269 | $3,228 |
| Atorvastatin Calcium | 226 | $2,595 |
| Losartan Potassium | 147 | $1,484 |
| Rosuvastatin Calcium | 173 | $1,446 |
| Metoprolol Tartrate | 239 | $1,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $129 | $135,566129 claims |
| Sanofi-aventis U.S. LLCMultaq | $49 | $17,94913 claims |
| NovartisEntresto | $16 | $13,39716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Kalispell
- Rawa SarjiKalispell$2K
- Eve GillespieKalispell$1K
- Alexis HarrisonKalispell$1K
- Joseph KrezowskiKalispell$1K
- Sharon HeckerKalispell$290
- David RothKalispell$18
- Benjamin PlankBillings$46K
- Alrich GrayGreat Falls$34K
- Jocelyn SpoonMissoula$17K
- Patricia KellyMissoula$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.